Drugs / AS-703988
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01453387 | Sep 2011 → Jul 2013 | neoplasm | EMD Serono | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AS-703988 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545243 ↗ |
| Known as | MSC2015103B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01453387 ↗ |
| Action | Inhibit | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL3545243 ↗2“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL3545243 ↗ “Oral MEK Inhibitor MSC2015103B” NCT01453387 ↗ |
| Route | Oral | “MSC2015103B will be administered orally once weekly” NCT01453387 ↗ |
| Target | MAP2K1 | “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL3545243 ↗ |
| Target | MAP2K2 | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL3545243 ↗ |